The FDA approved HUMIRA® (adalimumab) for the treatment of moderate to severe hidradenitis suppurativa (HS) in adults. HUMIRA is a prescription medicine manufactured by AbbVie, a global pharmaceutical company based in Chicago, IL and is indicated for the relief of symptoms of several inflammatory autoimmue diseases including rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, Crohn’s disease and ulcerative colitis. It is a fully human monoclonal antibody that can bind tumor necrosis factor-alpha (TNFa), preventing it from binding to TNFa receptor thus reducing the associated inflammatory responses. HS is a rare chronic inflammatory skin disorder with an autoimmune nature. It is characterized by inflamed and painful skin lesions that most commonly located around the armpits, under the breasts, buttocks and groin. The exact cause of HS is unknown and there is currently no effective treatment. Two Phase III clinical trials involving over 600 people with moderate to severe HS have demonstrated the clinical efficacy of HUMIRA in reducing the total number of abscesses and inflammatory nodules.